סימבקסון 40

Land: Israel

Språk: hebreiska

Källa: Ministry of Health

Köp det nu

Bipacksedel Bipacksedel (PIL)
06-07-2021

Aktiva substanser:

SIMVASTATIN

Tillgänglig från:

DEXCEL PHARMA TECHNOLOGIES LTD

ATC-kod:

C10AA01

Läkemedelsform:

קפליות

Sammansättning:

SIMVASTATIN 40 MG

Administreringssätt:

פומי

Receptbelagda typ:

מרשם נדרש

Tillverkad av:

DEXCEL LTD, ISRAEL

Terapeutisk grupp:

SIMVASTATIN

Terapiområde:

SIMVASTATIN

Terapeutiska indikationer:

Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvaxon is indicated to: - Reduce the risk of total mortality by reducing coronary death - Reduce the risk of non-fatal myocardial infarction - Reduce the risk for undergoing myocardial revascularization procedures - Reduce the risk of stroke and transient ischemic attacks (TIA's). Hyperlipidemia: Simvaxon is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia ( heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvaxon therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvaxon is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hype

Produktsammanfattning:

Atorvastatin, Cerivastatin, Fluvastatin, Lovastatin, Pravastatin, Simvastatin

Tillstånd datum:

2020-04-30

Dokument på andra språk

Bipacksedel Bipacksedel engelska 20-01-2021
Offentlig bedömningsrapport Offentlig bedömningsrapport engelska 18-08-2016
Bipacksedel Bipacksedel arabiska 20-01-2021

Sök varningar relaterade till denna produkt